REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 23rd, 2018 • InvaGen Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (as may be amended or modified from time to time, this “Agreement”) is made and entered into as of [•] by and among Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), and InvaGen Pharmaceuticals Inc., a New York corporation (“Buyer”).
JOINT FILING AGREEMENTJoint Filing Agreement • November 23rd, 2018 • InvaGen Pharmaceuticals, Inc. • Pharmaceutical preparations
The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.
SHARE REPURCHASE AGREEMENTShare Repurchase Agreement • July 28th, 2022 • InvaGen Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS SHARE REPURCHASE AGREEMENT (this “Agreement”) is made and entered into as of this 25th day of July, 2022 (the “Execution Date”), by and among InvaGen Pharmaceuticals Inc., a New York corporation (“InvaGen”), Avenue Therapeutics, Inc., a Delaware corporation (“Avenue”), and Fortress Biotech, Inc., a Delaware corporation (“Fortress”). Each of InvaGen, Avenue and Fortress is a “Party,” and, collectively, they are the “Parties.”
